SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.

Tools

The information used on this page will not be used to send unsolicited emails or shared with a third party.

HPF:

Fiscal Year 2009 Casefinding List

The Fiscal Year 2009 Comprehensive ICD-9-CM Casefinding and Supplementary ICD-9-CM Code Lists are to be used to identify cases diagnosed January 1, 2009 and later. The revised tables include new and expanded ICD-9-CM codes. The revised tables also now include paraneoplastic syndromes indicated by * in Explanation of Code.

The 2009 Comprehensive ICD-9-CM Casefinding Code List is designed to assist in casefinding activities that are performed to identify reportable neoplasms, including benign brain and CNS tumors which became reportable in 2004, among a variety of casefinding sources that use ICD-9-CM* codes (modified October 2008) to characterize a diagnosis.

Many new codes and conditions have been added to the Supplementary ICD-9-CM Code List. It is recommended that each registry screen cases using the supplementary list as time permits. Experience among the SEER registries has proven that using the supplementary list significantly improves casefinding outcomes for benign brain and CNS tumors, hematopoietic and lymphoid neoplasms, and other reportable diseases.

NOTE: Cases with these codes should be screened only as registry time allows. Some codes represent neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Complete casefinding would include investigation of patient records with diagnoses represented on either list.

Acquired Immunodeficiency Syndrome (AIDS) (This is not a malignancy. Medical coders are instructed to add codes for AIDS-associated malignancies. Screen 042 for history of cancers that might not be coded.)

Encounter for antineoplastic chemotherapy and immunotherapy (This code was discontinued as of 10/2006 but should be included in extract programs for quality control purposes)

V58.11

Encounter for antineoplastic chemotherapy

V58.12

Encounter for antineoplastic immunotherapy

V58.42

Aftercare following surgery for neoplasm

V66.1

Convalescence following radiotherapy

V66.2

Convalescence following chemotherapy

V67.1

Radiation therapy follow up

V67.2

Chemotherapy follow up

V76.0 – V76.9

Special screening for malignant neoplasm

V78.0 – V78.9

Special screening for disorders of blood and blood-forming organs

V82.71

Screening for genetic disease carrier status

V82.79

Other genetic screening

V82.89

Genetic screening for other specified conditions

V82.9

Genetic screening for unspecified condition

V84.01 – V84.09

Genetic susceptibility to malignant neoplasm

V86.0

Estrogen receptor positive status [ER+]

V86.1

Estrogen receptor negative status [ER-]

V87.41

Personal history of antineoplastic chemotherapy

NOTES:

Prostatic Intraepithelial Neoplasia (PIN III) M-8148/2 will NOT be collected by SEER registries.

Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior a /3 (malignant). Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER registries.

The World Health Organization (WHO) diagnosis "B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma" is coded as 9823/3, and cross-referenced to 9670/3, malignant lymphoma, small B lymphocytic, NOS. If this WHO term is used to describe malignancy in blood or bone marrow, code 9823/3; if the term is used to describe malignance in tissue, lymph nodes or any organ in combination with blood or bone marrow, code 9670/3.